Autolus Therapeutics plc ADR [NASDAQ: AUTL] traded at a high on 2025-09-24, posting a 15.56 gain after which it closed the day’ session at $1.56.
The results of the trading session contributed to over 9825796 shares changing hands. Over the past one week, the price volatility of Autolus Therapeutics plc ADR stands at 8.35% while the volatility over the past one month is 6.93%.
The market cap for AUTL stock reached $415.18 million, with 266.14 million shares outstanding and 240.33 million shares in the current float. Compared to the average trading volume of 2.93M shares, AUTL reached a trading volume of 9825796 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Autolus Therapeutics plc ADR [AUTL]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for AUTL shares is $9.46 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on AUTL stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Goldman have made an estimate for Autolus Therapeutics plc ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 18, 2024. The new note on the price target was released on November 15, 2024, representing the official price target for Autolus Therapeutics plc ADR stock. Previously, the target price had yet another raise to $10, while Deutsche Bank analysts kept a Buy rating on AUTL stock.
The Price to Book ratio for the last quarter was 1.60, with the Price to Cash per share for the same quarter was set at 1.71.
How has AUTL stock performed recently?
Autolus Therapeutics plc ADR [AUTL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 22.83. With this latest performance, AUTL shares dropped by -2.50% in over the last four-week period, additionally sinking by -3.70% over the last 6 months – not to mention a drop of -33.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for AUTL stock in for the last two-week period is set at 50.96, with the RSI for the last a single of trading hit 0.1085, and the three-weeks RSI is set at 0.1163 for Autolus Therapeutics plc ADR [AUTL]. The present Moving Average for the last 50 days of trading for this stock 1.8911, while it was recorded at 1.3980 for the last single week of trading, and 1.9413 for the last 200 days.
Autolus Therapeutics plc ADR [AUTL]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Autolus Therapeutics plc ADR [AUTL] shares currently have an operating margin of -894.57% and a Gross Margin at -107.53%. Autolus Therapeutics plc ADR’s Net Margin is presently recorded at -755.73%.
Autolus Therapeutics plc ADR (AUTL) Capital Structure & Debt Analysis
According to recent financial data for Autolus Therapeutics plc ADR. ( AUTL), the Return on Equity (ROE) stands at -52.18%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -28.97%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Autolus Therapeutics plc ADR’s Return on Invested Capital (ROIC) is -34.96%, showcasing its effectiveness in deploying capital for earnings.
Autolus Therapeutics plc ADR (AUTL) Efficiency & Liquidity Metrics
Based on Autolus Therapeutics plc ADR’s (AUTL) latest financial statements, the Debt-to-Equity Ratio is 0.91%, indicating its reliance on debt financing relative to shareholder equity.
Autolus Therapeutics plc ADR (AUTL) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Autolus Therapeutics plc ADR. (AUTL) effectively leverages its workforce, generating an average of -$352534.78 per employee. The company’s liquidity position is robust, with a Current Ratio of 8.38% and a Quick Ratio of 8.03%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Autolus Therapeutics plc ADR [AUTL]
With the latest financial reports released by the company, Autolus Therapeutics plc ADR posted -0.31/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.09. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for AUTL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Autolus Therapeutics plc ADR go to 16.12%.
Insider trade positions for Autolus Therapeutics plc ADR [AUTL]
There are presently around $84.03%, or 102.59%% of AUTL stock, in the hands of institutional investors. The top three institutional holders of AUTL stocks are: SYNCONA PORTFOLIO LTD with ownership of 21.35 million shares, which is approximately 8.0243%. BLACKSTONE INC., holding 20.49 million shares of the stock with an approximate value of $$71.29 million in AUTL stocks shares; and BLACKSTONE INC., currently with $$62.26 million in AUTL stock with ownership which is approximately 6.7248%.
